A drug recently approved for treatment of opioid-induced constipation would be removed from Schedule II control under a proposal by the Drug Enforcement Administration (82 Fed. Reg. 32153; July 12, 2017). On March 23, naldemedine was approved by the U.S. Food and Drug Administration to be marketed under the trade name Symproic. Currently, it is a Schedule II controlled substance b... Read More